Overview

Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The virological efficacy will be no different in children treated with single versus double boosted PI second line ART regimens.
Details
Lead Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborator:
Ministry of Education, Thailand
Treatments:
HIV Protease Inhibitors
Protease Inhibitors
Reverse Transcriptase Inhibitors
Ritonavir